Ai Injection Research Articles

Cost-effectiveness of Kang Ai injection plus chemotherapy vs. Shenqi Fuzheng injection plus chemotherapy in the first-line treatment of advanced non-small cell lung cancer.

This study aimed to evaluate the cost-effectiveness of two Chinese patent medicines, including Kang Ai injection and Shenqi Fuzheng injection with each combined with platinum-based chemotherapy as the first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) in China. From Chinese healthcare system perspective, a three state Markov model with a cycle of 3 weeks and a 10-year horizon was constructed to derive the incremental cost-effectiveness ratio (ICER). Since only individual patient data of progression-free survival (PFS) of Kang Ai injection group can be obtained, we extrapolated median overall survival (mOS) of Kang Ai injection group and median progression-free survival (mPFS) and mOS of Shenqi Fuzheng injection group based on published literature and methods. Then survival curves were estimated by the method of declining exponential approximation of life expectancy (DEALE), which is based on the assumption that survival follows a declining exponential function. We performed one-way sensitivity analysis and probabilistic sensitivity analysis to test the robustness. Additionally, a scenario analysis was adopted to investigate the impact of using best-fitting distribution for PFS curve of Kang Ai injection group on the economic conclusion. The base-case result indicated that Kang Ai injection group provided 0.217 incremental quality-adjusted life years (QALYs) at an incremental cost of $103.38 compared with Shenqi Fuzheng injection group. The ICER was $476.41/QALY, which was much lower than the willingness to pay threshold of one time the GDP per capita of China in 2022 ($12,070/QALY). Deterministic sensitivity analysis result showed that ICER was most sensitive to the changes in odds ratio (OR) value. The probabilistic sensitivity analysis confirmed the robustness of base-case analysis results. The scenario analysis result showed that by using Log-Normal distribution to fit the PFS curve of Kang Ai injection group and shortening the time horizon to 5 years, the ICER was $4,081.83/QALY, which was still much lower than the willingness to pay threshold. Kang Ai injection combined with platinum-based chemotherapy appeared to be more cost-effective for the treatment of advanced NSCLC than Shenqi Fuzheng injection combined with platinum-based chemotherapy.

Meta-analysis of therapy of Kang’ai injection combined with chemotherapy in the treatment of non-small cell lung cancer

Meta-analysis of therapy of Kang’ai injection combined with chemotherapy in the treatment of non-small cell lung cancer

Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.

Objective:We conducted this study to evaluate the efficacy and safety of traditional Chinese medicine (TCM) in advanced non-small cell lung cancer (NSCLC) patients who underwent chemotherapy.Design:This was a prospective, open-label, randomized controlled trial. NSCLC patients at stage IIIA, IIIB, or IV were randomly assigned to either TCM plus chemotherapy or chemotherapy alone. The comprehensive TCM treatment consisted of Kang Ai injection, herbal decoction, and Zhenqifuzheng capsules. The primary endpoint was quality of life (QOL) measured by the Functional Assessment of Cancer Therapy-Lung version 4.0. The secondary endpoints were chemotherapy completion rate, tumor response, and adverse events. All assessments were done at baseline, the third week, and the sixth week.Results:Thirty-nine participants were randomly assigned to the treatment group and 36 to the control group. The QOL scores were significantly improved in the treatment group compared with those of the control group in social well-being (cycle 1, P = .048; cycle 2, P = .015), emotional well-being (cycle 1, P = .047; cycle 2, P = 4.29E-05), and functional well-being (cycle 1, P = .030; cycle 2, P = .003), while the QOL scores in the above 3 domains declined in the control group (P < .05). Both groups had a decline in the physical well-being score (cycle 1, P = .042; cycle 2, P = .017) and lung cancer symptom score (cycle 1, P = .001; cycle 2, P = .001) after 2 courses of intervention. The deterioration in physical well-being and lung cancer symptoms was noticeably smaller in the treatment group (P < .05). There were significant differences between the 2 groups in social well-being, emotional well-being, functional well-being, lung cancer symptom domain, and the total score (P < .05). Patients in the treatment group had a significantly lower incidence of platelet reduction than the control group (P = .028) after 2 cycles of treatment. No significant difference in nonhematological adverse events (AEs) was observed.Conclusion:This study illustrated that comprehensive TCM treatment could promote the QOL of NSCLC patients, alleviate symptoms, and reduce the AEs caused by chemotherapy, verifying the synergistic and attenuating effects of TCM in NSCLC patients undergoing chemotherapy.Trial registration:Chinese Clinical Trial Registry (www.chictr.org.cn): ChiCTR-TRC-13003637

Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang’ai injection and chemotherapy irinotecan hydrochloride injection by LC–MS/MS

Chinese herbal drugs are often combined with chemotherapy drugs for the treatment of cancers. However, the combination administrations often do not have scientifically sound bases established on full preclinical and clinical investigations. A commonly used anti-colon-cancer herb-drug pair, irinotecan (CPT-11) hydrochloride injection and Kang’ai (KA) injection was taken as an example to investigate the possible pharmacokinetic interactions between Chinese herbal drugs and chemotherapy injections to determine the potential adverse drug reactions (ADRs). Rats were randomly divided into three groups and received 20 mg/kg CPT-11 injection 15 min after administration of 4 mL/kg saline for the CPT-11 single administration group and 4 mL/kg KA injection for the separated co-administration group, respectively. In the pre-mixed co-administration group, rats received a mixture of 20 mg/kg CPT-11 injection and 4 mL/kg KA injection. Blood samples were collected at 10 pre-determined time points between 0 and 24 h. The tissue samples were collected at 5 and 8 min after the injections, respectively. A reliable LC–MS/MS method was established for the simultaneous determination of CPT-11 and its metabolites, SN-38, SN-38 G and APC in the rat plasma and tissue samples, after full confirmation of two injections chemical and stability compatibilities. Compared to the C0 (5129 ± 757 ng/mL) and AUC0-t (7858 ± 1307 ng h/mL) of CPT-11 in the CPT-11 single administration group, the C0 (4574 ± 371 ng/mL) and AUC0-t (8779 ± 601 ng h/mL) after the separated co-administration remained unchanged, but the pre-mixed co-administration resulted with a significant increased C0 (29,454 ± 12,080 ng/mL) and AUC0-t (15,539 ± 5165 ng h/mL) (p < 0.05). Since the exposures of CPT-11 in most tissues in the pre-mixed co-administration group were dramatically lower than the separated co-administration group, the increased CPT-11 plasma concentration may be produced by the delayed tissue distribution because of the encapsulation by the components contained in KA injection, such as polysaccharides. Similar differences were also found in its metabolite, SN-38 G. There are obvious herb-drug interactions between CPT-11 injection and KA injection after the pre-mixed co-administration. The resulting excessive CPT-11 in the plasma may lead to many serious ADRs. Therefore, the full evaluation of herb-drug interactions is necessary and inappropriate combinations should be avoided.

Network pharmacology to predicting therapy targets of traditional Chinese medicine Kang’ai injection on breast cancer

Network pharmacology to predicting therapy targets of traditional Chinese medicine Kang’ai injection on breast cancer

Efficacy and safety of Kang’ai injection adjunct with TP chemotherapy for the treatment of non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of Kang’ai injection adjunct with TP chemotherapy for the treatment of non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

A Multi-center Randomized Controlled Clinical Study of Kang'ai Injection Combined with OFL Regimen on Gastric Cancer Patients

A Multi-center Randomized Controlled Clinical Study of Kang'ai Injection Combined with OFL Regimen on Gastric Cancer Patients

Magnetic dispersive solid-phase extraction for the determination of three different glycosides in the Kang'ai injection

In this work, the content of flavonoid glycosides and astragalosides in a Chinese medicine injection was determined by using the magnetic dispersive solid phase extraction method coupled with high performance liquid chromatography with an evaporative light-scattering detector (HPLC/ELSD). Multi-walled carbon nanotubes (MWCNTs) modified by Fe3O4 nanoparticles obtained in a one-step synthetic procedure, were used as a sorbent to conveniently remove the analytes from water. Single factor experiments were performed to investigate the factors that affected the extraction efficiency, such as the hydroxyl content of the modified MWCNTs, the amount of sorbent, the type of elution solvent, the volume of elution solvent, sample pH and salting-out effect. Under the appropriate optimal conditions, the limits of detection (LODs) and limits of quantification (LOQs) for the three glycosides ranged from 0.16 μg/mL to 0.60 μg/mL and 0.58 μg/mL to 1.24 μg/mL, respectively. Moreover, the intra- and interday precision ranged from 1.9% to 2.9% and 2.4% to 4.5%, respectively. Meanwhile, the recoveries of spiked samples were measured, which ranged from 91.1% to 96.2% with relative standard deviations (RSDs) ranging from 2.8% to 3.8%. Accordingly, the application of the proposed method for the analysis of Chinese medicine injection samples offered several advantages: an acceptable precision, low LODs and good recoveries. This work might provide a research basis for the quality control of Chinese medicine injections and the further study of the Kang'ai injection.

Centrifugation free and air-assisted liquid-liquid microextraction based on deep eutectic solvent for determination of rare ginsenosides in Kang'ai injection

A simple, effective and convenient enrichment method coupled with high performance liquid chromatography (HPLC) was established for the analysis of rare ginsenosides in Kang'ai (KA) injection. Air assisted liquid-liquid microextraction was used in this work for the first time to determine the rare ginsenosides in KA injection. Deep eutectic solvent (DES) and tetrahydrofuran (THF) were specially selected as a novel green extraction solvent and an emulsified solvent, respectively. To remove the DES droplets, Fe3O4 nanoparticles were used. Therefore, centrifugation was free in this work, which can increase the efficiency of analysis procedure. Moreover, Fe3O4 nanoparticles were reusable. To achieve better extraction efficiency and enrichment factor, the experimental conditions have been optimized, including type and volume of DES and emulsified solvent, amount of Fe3O4 nanoparticles and inorganic salt, and pH value. Under the optimum extraction condition, the validation parameters show the limits of detection (LODs) are in the range from 10.2 ng/mL to 137.8 ng/mL and the limits of quantity (LOQs) are in the range from 55.5 ng/mL to 428.5 ng/mL. The recoveries of analytes range from 91.3% to 106.7% with the relative standard deviations (RSDs) ranging from 1.2% to 4.5%. The recommended approach was utilized to acquire the information of constituents in KA injection. Moreover, the results in this research could provide a study basis for further study of KA injection.

Impact of Single or Multiple Doses of Pregnant Mare Serum Gonadotropin (PMSG) on Superovulatory Response of Post-Partum Friesian Cows

This study aimed to compare the effect of using PMSG at a level of 2500 IU in term of one dose, two doses (1250 IU for each at 12 h interval) or 4 doses (650 IU for each at 12 h interval) on superovulatory response (SOVR), and yield and quality of embryos. A total of 21 Friesian cows (450-550 kg LBW, 3.5-5.5 y old and 1-3 parities) were used as embryo donors. Cows were fed and managed under the same conditions. All cows were i.m. injected with 3 ml PGF2α/cow (Estrumate) for estrous synchronization. Cows in the 1st protocol (P1) were i.m. injected with one dose of PMSG (2500 IU/cow) on day 10 of estrous cycle (control), while those in the 2nd and 3rd protocols were i.m. injected with two doses of PMSG (1250 IU/dose/cow) at 12 h interval on day 10 of estrous cycle (P2) and with four doses of PMSG (625 IU/dose/cow) at 12 h interval on day 10 and 11 of estrous cycle (P3), respectively. After 48 hours of the last PMSG dose in all protocols, all cows were i.m. injected with 2 ml PGF2α/cow. Both AI and GnRH (5 ml Receptal/animal) injections were done on day 14 in P1 and P2 and day 15 in P3. Embryos were un-surgically flushed 7 days post-AI. Number of total follicles (TFN), large follicles (LFN) and CLs (CLN), and diameter of follicles/cow on day of AI and flushing were determined. Ovulation rate (OR), embryo recovery rate (ERR) and quality of non-surgically recovered 7 days post-AI were determined. Results showed that on day of AI, FN, LFN and follicular diameter tended to be the highest in P3, moderate in P2 and the lowest in P1. On day of flushing, total and large follicles were the greatest and the widest in P2, followed by P1, and the least and the narrowest in P3. Ovulatory sites (CLN) was greater in P1 and P3 (2.00 and 2.07/ovary) than in P2 (1.57/ovary). The effect of protocol, ovarian side and their interaction on follicular number and diameter, and CLs number was not significant on AI and flushing days. The response to CLs formation on day of flushing on the right, left or both ovaries was 100% in each protocol. Showing CLs was higher on the right than on the left ovaries in P1 (85.7 vs. 71.4%), being the opposite (71.4 vs. 85.7%) in P2 and similar in P3 (85.7 on each side). OR was higher (P<0.05) in P1 than in P2 (69.9 vs. 52.3%), but did not differ in P3 (59.1%) from that in P1 and P2. Percentage of cows produced embryos was highest in P3 (71.4%), moderate in P1 (57.1%) and the lowest in P2 (14.2%) with average number of 1.71, 1.86 and 0.57 embryos/cow, respectively. ERR was higher in P1 and P3 (46.5 and 41.3%) than in P2 (18.1%). About 25% of cows in P1 produced 5 embryos, and 40% in P3 produced 2 embryos versus one cow in P2 (14.3%) produced 4 embryos. Distribution of embryos at morula stage was higher (50%) in P2 than in P1 (30.8%) and P3 (33.4%). Distribution of embryos at compact morula stage was the highest in P1 and P3 (53.8 and 41.7%) than in P2 (25%) versus 15.4 and 16.6% at blastocyst stage in P1 and P3. Distribution of transferable embryos was 95.3, 50.0 and 83.3% in P1, P2 and P3, respectively. Superovulation of Friesian cows with PMSG (2500 IU/cow) on day 10 of the estrous cycle, in term of 4 doses (625 IU) at 12-h interval, showed the best follicular response (number and diameter) on day of AI and the higher ovulatory response, in term of number of un-ovulated follicles and CLs as well as percentage of cows responded to produce embryos (71.4%) on day of flushing. The same PMSG as a single dose showed the highest response, in term of number of transferable embryos/cow (1.71/cow).

Determination of common ginsenosides in Kang'ai injection by aqueous two-phase extraction with deep eutectic solvents and HPLC-UV/DAD

In this work, four kinds of deep eutectic solvents (DESs), composed of choline chloride (ChCl) and several alcohols, were synthesized and characterized by 1H NMR and FT-IR spectra. Based on DES (ChCl and 1,4-butanediol) and inorganic salt solution (dipotassium phosphate, K2HPO4), aqueous two-phase system (ATPS) coupled with high-performance liquid chromatography has been developed and applied. This method was used for the efficient extraction and determination of eight common ginsenosides (including ginsenoside Rg1, Re, Rf, Rg2, Rb1, Rc, Rb2 and Rd) in the traditional Chinese medicine injection named Kang'ai injection. To achieve optimum extraction performance, the experimental conditions were optimized, including type and amount of DES and salt, ultrasound time, temperature and pH value. In the dynamic linearity range, experimental results showed satisfactory recoveries of analytes ranging from 92.7–110.8% with the relative standard deviations (RSDs) ranging from 1.2–3.9%. It has been proved that DES-ATPS has great potential for determination of active ingredients in traditional Chinese medicine injection as well as samples in other analytical science field.

The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study.

Background: The outcome of patients with intermediate stage hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) remains poor. Search for a more effective therapy is still necessary. Objective: This study aimed to investigate the effect of combining TACE with Kang’ai (KA) injection for treating patients with intermediate stage HCC. Methods: A total of 89 patients with intermediate stage HCC were enrolled and divided into TACE +KA group (n = 48) receiving repeated TACE plus KA injection, and TACE group (n = 41) receiving repeated TACE alone. All patients were prospectively studied. Primary endpoints were overall survival (OS) and time to radiologic progression (TTP). Results: The TACE + KA group had significantly longer median OS (27.0 vs 21.0 months, P = .038) and TTP (12.0 vs 10.0 months, P = .028) than TACE group. The 1-, 2-, and 3-year OS rates in the TACE + KA group were markedly higher than in TACE group (88.5%, 58.8%, and 20.8% vs 81.3%, 44.9%, and 6.7%, respectively, P = .038), while the 1- and 2-year TTP rates in the TACE + KA group were significantly lower than in TACE group (49.3% and 86.9% vs 75.3% and 100%, P = .028). TACE + KA group displayed significantly lower incidences of intrahepatic and extrahepatic metastases, as well as postembolization syndrome than TACE group (P < .05). Multivariate analyses revealed group (P = .023), maximum tumor size (P = .019), and tumor number (P = .034) as significant predictors for OS, and group (P = .046), maximum tumor size (P = .002) and α-fetoprotein level (P = .020) as significant predictors for TTP. Both TACE and KA injection were well tolerated. Conclusion: TACE plus KA injection is more effective than TACE alone for treating patients with intermediate stage HCC in this nonrandomized study. Further research is warranted.

Injectable Chinese herbal formula Kang'ai for nonsmall cell lung cancer: Trial sequential analysis of 2,259 participants from 31 randomized controlled trials.

The aim was to evaluate the efficacy and safety of Kang' ai (KA) injection for patients with nonsmall cell lung cancer (NSCLC). Furthermore, to identify if more trials are needed before reliable conclusions could be drawn with regard to these outcomes. We searched the Cochrane library, PubMed, EMBASE, VIP, CBMdisc, and CNKI in September 2012, and then an additional updated search was conducted in January 2013. Only relevant randomized controlled trials (RCTs) on KA injection plus first-line cisplatin-based chemotherapy in the treatment of NSCLC were identified. Trials' data was reviewed and extracted by two reviewers independently. The quality of included studies was assessed according to a statement from Cochrane Handbook. RevMan 5 Software and Trial sequential analysis (TSA) software were applied for data analyses. A total of 31 RCTs involving 2259 patients were included. The results of meta-analysis showed that compared with chemotherapy alone, the combination of KA injection plus chemotherapy had a statistically significant benefit in improving clinical response rate (relative risk [RR] =1.29, 95% confidence interval [CI]: 1.17-1.41, P < 0.00001), clinical benefit rate (RR = 1.19, 95% CI: 1.14-1.25, P < 0.00001) and quality of life (RR = 1.79, 95% CI: 1.63-1.98, P < 0.00001); hematological toxicity (white blood cell) (RR = 0.71, 95% CI: 0.66-0.76, P < 0.00001) and nonhematological toxicity (nausea and vomiting) (RR = 0.73, 95% CI: 0.65-0.83, P < 0.00001) were improved as well. TSA showed that all cumulative Z-score crossed their monitoring boundaries, demonstrating that no more trials are needed before reliable conclusions could be drawn. Current evidence presented that KA injection might improve the therapeutic effect when combined with chemotherapy. Moreover, no more trials are needed in future according to TSA. Nevertheless, additional randomized studies investigating KA injection are needed to be further evaluated.

Evaluation of the combined treatment of oral viscosupplementation with hyaluronic acid intra-articular injection on symptomatic knee osteoarthritis

Numerous clinical evidences support the treatment of knee OA (KOA) with oral formulations based on hyaluronic acid (HA) and chondroitin sulfate (CS). The formulation aim of the present study (IA) combines a hydrolyzed low molecular weight collagen matrix providing high content of depolymerised HA and CS, with methylsulfonylmethane (MSM), Manganese and a milk glycoprotein. The goal was to evaluate whether combined treatment with intra - articular injection of HA and AI is more effective than treatment with HA only for the symptomatic treatment of knee OA. Randomized, double-blind, placebo-controlled clinical trial. Patients (nr = 100), after undergoing an intra-articular injection with HA, were randomized to receive IA or placebo for 3 months. The efficacy of the treatment was assessed by measuring at baseline, 1 and 3 months, the values of the VAS pain scale, the Knee injury and Osteoarthritis Outcome Score, the Tegner Lysholm Knee Scoring Scale, Lequesne algofunctional index and the consumption of NSAIDs and analgesics. The treatment group HA + IA showed a positive trend compared to the group treated with HA only for all the efficacy variables observed, in particular regarding the VAS and the analgesic consumption. The evidences obtained in this study point out that the oral viscosupplementation with the formulation aim of the present study (IA) represents a valuable, manageable, effective and well tolerated aid, useful to maintain and extend the benefits obtained with intra - articular injection of HA, helping to significantly reduce the use of painkillers by patients.

A meta-analysis of Kang`ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer.

The purpose of this study was to evaluate the Kang`ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) by meta-analysis. Electronic search of the Cochrane library, PubMed, EMBASE, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), VIP Database for Chinese Technical Periodicals (VIP), and Wanfang Database was conducted to collect appropriate studies about Kang`ai injection combined with chemotherapy versus chemotherapy alone in the treatment of NSCLC. All data were analyzed by using RevMan 5.2 software provided by Cochrane, which involved the odds ratio (OR) and 95% confidence intervals (95% CIs) calculated with fixed-effect models according to the heterogeneity test. Eighteen studies were included in this meta-analysis. The meta-analysis showed that Kang`ai injection combined with chemotherapy could enhance the efficacy of the tumor response (OR=1.51, 95% CI: 1.23-1.85, Z=3.94, P<0.0001), improve the quality of life (OR=3.37, 95% CI: 2.71-4.20, Z=10.86, P<0.00001), alleviate the adverse reaction of digestive tract (OR=0.42, 95% CI: 0.32-0.55, Z=6.34, P<0.00001) and reduce the risk of the bone marrow suppression (OR=0.38, 95% CI: 0.29-0.49, Z=7.37, P<0.00001) compared with chemotherapy alone. Asymmetries were observed in funnel plots, which indicated an evidence of publication bias. Kang`ai injection combined with chemotherapy can enhance the short-term efficacy, improve the quality of life, and alleviate the chemotherapy-induced adverse reaction in the treatment of advanced NSCLC, although these results need to be further confirmed by more high-quality trials.

The insular auditory field receives input from the lemniscal subdivision of the auditory thalamus in mice

Here we studied the auditory thalamic input to the insular cortex using mice as a model system. An insular auditory field (IAF) has recently been identified in mice. By using retrograde neuronal tracing, we identified auditory thalamic neurons projecting to the IAF, primary auditory cortex (AI), and anterior auditory field (AAF). After mapping the IAF, AAF, and AI by using optical imaging, we injected a distinct fluorescent tracer into each of the three fields at frequency-matched locations. Tracer injection into the IAF resulted in retrogradely labeled cells localized ventromedially in the lemniscal division, i.e., the ventral subdivision of the medial geniculate body (MGv). Cells retrogradely labeled by injections into the AAF were primarily found in the medial half of the MGv, whereas those from AI injections were located in the lateral half, although some of these two subsets were intermingled within the MGv. Interestingly, retrogradely labeled cells projecting to the IAF showed virtually no overlap with those projecting to the AAF or the AI. Dual tracer injections into two sites responding to low- and high-frequency tones within each of the three auditory fields demonstrated topographic organizations in all three thalamocortical projections. These results indicate that the IAF receives thalamic input from the MGv in a topographic manner, and that the MGv–IAF projection is parallel to the MGv–AAF and MGv–AI projections.

Observation on the effects of Kang'ai injection and Shenqifuzheng injection on liver function of patients with advanced primary liver cancer after interventional procedure

Objective To investigate the effect of Kang' ai injection and Shenqifuzheng injection on liver function of patients with advanced primary liver cancer after being performed transcatheter arterial chemomembolization (TACE).Methods 120 patients with advanced primary liver cancer were randomly divided into three groups:a control group,a Kang'ai injection group,and a Shenqifuzheng injection group,with 40 patients in each group.All three groups were treated with TACE,and after TACE the control group was treated with anti-infection,inhibiting-acid,protecting-liver function and Shuganning tablets,20 ml/day.On this basis,the Kang'ai injection group was additionally injected with Kang'ai injection,40ml/day,and Shenqifuzheng injection group was additionally injected with Shenqifuzheng injection,250ml/day.All three groups were treated for 15 days.Liver function was tested and compared at the 3rd day,the 7th day and 14th day after TACE in all three groups.Results At the 14th day after TACE,ALT,AST,TBiL,and TBA of the Kang' ai group and Senqifuzheng group [(40.35 ± 10.10) μmol/L、(37.52 ± 10.57) μmol/L、(40.13 ± 8.36) μmol/L、(45.19 ± 19.65) μmol/L in Senqifuzheng group; (40.11 ±7.31) μmol/L,(34.99±9.38) μmol/L,(32.15±6.58) μmol/L,(40.75 ± 6.79) μmol/L in Kang'ai group] were greatly improved than the control group [(61.28 ± 13.38) μmol/L,(57.53 ± 13.36) μmol/L,(68.69± 7.25) μmol/L,(67.75 ± 17.88) μmol/L],with statistical significance (P＜ 0.01).Conclusion Kang'ai injiection and Shenqifuzhcng injection both can reduce liver function damage caused by TACE,thus they can be used together with TACE for treating advanced primary liver cancer. Key words: Kang'ai injection; Shenqifuzheng injection; Advanced primary liver cancer; Transcatheter arterial chemoembolization; Liver function

Randomized controlled clinical trial of Kang'ai injection in gastrointestinal cancerchemotherapy patients

To study the influence of kang'ai injection on quality of life among gastrointestinal cancer chemotherapy patients. Fourty-two gastrointestinal cancer patients were randomly divided into the treatment group (n=22) and the control group (n=20). The treatment group was treated with chemotherapy and kang'ai injection, and the control group was only treated with chemotherapy. Their quality of life, improvement of clinical symptoms and adverse effects were observed. The disease control rates of the treatment group and the control group were 91% and 30% ,while their effective rates of KPS were 59% and 30% respectively. They had one case and six cases with side effects above III degree. Kang'ai injection can mitigate syndromes of gastrointestinal cancer chemotherapy patient, improve their quality of life and have an effect of reducing toxic and enhancing efficacy for chemotherapy.

Analysis of Anti-cancer Traditional Chinese Medicine Injections based on Market Performance

Abstract Traditional Chinese medicine injections (TCMIs) have played vital roles in the treatment of cancer, cardiovascular diseases, virus and so on. This article analyzed the market of anti-cancer TCMIs in China, with special emphasis on Kang'ai Injection, Shenqi Fuzheng Injection, Aidi Injection, Lentinan Injection and Compound Kushen Injection, which presented excellent market performances. An analysis on the technical features and clinical applications of these five anti-cancer TCMIs was also conducted. Finally, we pointed out constraints and possible solutions to the development of anti-cancer TCMIs.

Effect of Kang'ai injection on hepatic fibrosis in rats

To investigate the inhibition role of Kang'ai injection (KAI) in rats with hepatic fibrosis. Animal model with liver fibrosis were induced by 0.01% concentration of diethylnitrosamine (DEN). 30 female Wistar rats (160-200 g) were randomly divided into 3 groups: the KAI-DEN group, the DEN group and the blank control group. The KAI-DEN group was administered Kang'ai injection (1 mL x k(-1), intraperitoneal injection, once a week) and the DEN group was administered normal saline intraperitoneal injection. HE staining and VG special staining of liver tissue were used to evaluate liver fibrosis. Compared with the DEN group, relatively less structural damage and less pseudolobular formation in the KAI-DEN group. Collagen area of the blank control group, the KAI-DEN group and the DEN group were (6.52 +/- 2.64)% , (17.41 +/- 1.112)% and (20.180 +/- 2.519)% , respectively. The difference was statistically significant, P < 0.05. Kang'ai injection could inhibit the formation of DEN-induced liver fibrosis.